<u>Journal of Virology</u>

1
т

2

GSK3732394: A multi-specific inhibitor of HIV entry

Running title: A Combinectin (combination adnectin) as a long acting inhibitor of HIV-1 3 David Wensel¹, Yongnian Sun², Jonathan Davis², Zhufang Li¹, Sharon Zhang¹, Thomas 4 McDonagh², David Langley², Tracy Mitchell², Sebastien Tabruyn³, Patrick Nef, ³ Mark Cockett¹ 5 and Mark Krystal^{1*} 6 7 ¹. ViiV Healthcare, Branford, CT, USA 8 ^{2.} Bristol-Myers Squibb, Wallingford, CT and Waltham, MA, USA 9 ^{3.} TransCure bioServices, Archamps, France 10 * Corresponding author: Mark.R.Krystal@viivhealthcare.com 11 12 13 14 Some of the data included in this manuscript was presented at the Conference for 15 Retroviruses and Opportunistic Infections (CROI), February 22-25, 2016, Boston Massachusetts, 16 Abstract 97. 17

19 Long-acting antiretrovirals could provide a useful alternative to daily oral therapy for HIV-1 20 infected individuals. Building on a bi-specific molecule with adnectins targeting CD4 and gp41, a 21 potential long-acting biologic, GSK3732394, was developed with three independent and synergistic 22 modes of HIV entry inhibition that potentially could be self-administered as a long-acting subcutaneous 23 injection. Starting with the bi-specific inhibitor, an alpha-helical peptide inhibitor was optimized as a 24 linked molecule to the anti-gp41 adnectin, with each separate inhibitor exhibiting at least single digit 25 nanomolar (or lower) potency and a broad spectrum. Combination of the two adnectins and peptide 26 activities into a single molecule was shown to have synergistic advantages in potency, resistance barrier 27 and in the ability to inhibit HIV-1 infections at low levels of CD4 receptor occupancy, showing that 28 GSK3732394 can work in trans on a CD4+ T cell. Addition of a human serum albumin molecule 29 prolongs the half-life in a human CD4 transgenic mouse, suggesting that it may have potential as a long 30 acting agent. To show that, GSK3732394 was highly effective in a humanized mouse model of infection. 31 GSK3732394 is currently in human studies.

32

33 Importance

There continue to be significant unmet medical needs for patients with HIV-1 infection. 34 One way to improve adherence and decrease the likelihood of drug-drug interactions in HIV-1 35 infected patients is through the development of long acting biologic inhibitors. Building on a bi-36 37 specific inhibitor approach targeting CD4 and gp41, a tri-specific molecule was generated with three distinct antiviral activities. The linkage of these three biologic inhibitors creates synergy 38 that offer a series of advantages to the molecule. The addition of human serum albumin to the tri-39 40 specific inhibitor could allow it to function as a long acting self-administered treatment for 41 patients with HIV infection. This molecule is currently in early clinical trials.

42

44 Antiretroviral drug discovery has evolved over the past decade. The availability of safe and effective single-pill regimens, first containing three or more antiretroviral agents and now 45 containing two antiretroviral agents (1, 2) have shifted the discovery paradigm for new agents 46 towards longer acting molecules that can potentially improve compliance, convenience and 47 prophylaxis. Thus, a once monthly regimen of injectable cabotegravir/rilpivirine is currently in 48 Phase 3 trials (3-5). Aside from small molecules, larger biologic molecules have many of the 49 50 properties desired for a long acting agent. The first long-acting biologic for treatment of HIV, ibalizumab, has been approved for biweekly IV administration in highly treatment experienced 51 (HTE) individuals (6) and PRO-140, a mAb targeted to the CCR5 co-receptor, remains in 52 clinical trials (7). 53

The isolation and optimization of ever improving broadly neutralizing antibodies (bnAbs) 54 to HIV-1 have opened up the possibility of their use for treatment and/or pre-exposure 55 prophylaxis as long acting agents. However, even with the most improved bnAbs, breadth of 56 activity remains an issue and models suggest that complete coverage would require multiple 57 58 bnAbs to different regions of gp160 (8-12). This has led to the development of bi- and trispecific molecules, whereby 2 or even 3 different bnAb specificities are combined into a single 59 60 IgG-like molecule (13-15). This may reduce the number of molecules required for complete coverage of circulating HIV-1 viruses, although it does not solve the problem of pre-existing 61 resistance to portions of these multi-specific molecules. In addition, targeting gp160 in a multi-62 specific biologic with a cell membrane-targeting moiety can greatly enhance the potency of an 63 64 anti-HIV biologic. For instance, attaching an HIV-1 fusion peptide inhibitor to a monoclonal antibody targeting CCR5 (16), attaching a cholesterol moiety to the C-terminus of an HIV-1 65

66

67 neutralizing HIV-1 monoclonal antibody (18), are all means to localize the peptide at the surface of the target cell membrane, and all dramatically increase the potency of the combined molecule 68 compared to the separate molecules. Also, bispecific antibodies consisting of anti-HIV-1 69 neutralizing antibody fragments targeting gp120 fused to ibalizumab or anti-CCR5 showed 70 synergistic increases in potency compared to the individual inhibitors (18, 19), while fusion of a 71 72 CD4-Ig molecule to a coreceptor-mimetic peptide provides greater potency, breath and a higher resistance barrier than broadly neutralizing antibodies (20, 21). Similarly, linking an adnectin 73 targeting the CD4 molecule with another adnectin targeting the N17 region of gp41 produced a 74 75 broad-spectrum inhibitor with enhanced potency (>500 fold), compared to the potencies of the individual adnectin components (22). Thus, localization of anti-HIV-1 entry inhibitors to the 76 target cell surface through a variety of methods can significantly increase their local 77 concentration at the site of action, thereby improving potency. GSK3732394 is a single biologic 78 79 composed of 3 independent inhibitors of HIV-1 virus entry. One of the inhibitors is an anti-CD4 80 adnectin that drives synergistic potency of the other two anti-gp41 inhibitors (22) (an adnectin and a helical peptide inhibitor). Each inhibitor by itself has an extremely wide breadth of activity 81 82 and should be active against the vast majority of circulating HIV-1 viruses. Thus, this single 83 biologic molecule should not have the same issue of coverage as mixtures of bnAbs. However, a downside to any biologic modifier is the potential for an immunogenic reaction that effectively 84 decreases the efficacy of the molecule. Although an adnectin is mainly derived from the 10th type 85 86 III fibronectin domain of human fibronectin (23-26), the sequence variations needed to allow specific binding to a target may increase immunogenicity of the molecule. Previously, clinical 87 88 studies with an adnectin (CT-322) targeting VEGRF-2 did induce an immunologic response in a

fusion peptide inhibitor (17) or linking an HIV-1 fusion peptide inhibitor to various places on a

subset of individuals, although these anti-drug antibodies did not affect CT-322 plasma concentrations or VEGF-A biomarker responses (27). Clinical trials of GSK3732394 that are intended to determine the safety, pharmacokinetics, and immunogenicity profile of the molecule have recently initiated.

93

94 **Results**

95 Addition of a peptide fusion inhibitor to the bispecific inhibitor. Previously, we had described the creation and development of a potent HIV-1 entry inhibitor containing two 96 independently generated adnectins targeted to either CD4 or the N17 region of gp41 (22, 28). 97 Adnectins are small proteins based on the 10th type III domain of human fibronectin that can be 98 99 subjected to *in vitro* selection to identify sequences with specific properties and can be thought 100 of as similar to the VH portion of an antibody (23-26). In an attempt to further improve the virologic properties of this bi-adnectin inhibitor, a third inhibitory domain was added to the end 101 of the anti-gp41 adnectin. This inhibitor is similar to the known fusion inhibitors developed for 102 103 HIV-1, consisting of an α -helical peptide that binds at the amino terminus of the heptad repeat 1 of gp41 (29-31), upstream of where the anti-gp41 adnectin binds (22). The following 104 105 considerations were employed in this inhibitor peptide design: optimal length; optimal positioning along gp41 relative to the anti-gp41 adnectin binding site; broad spectrum activity; 106 potency; low predicted immunogenic risk; and biophysical behavior (minimal tendency to 107 108 aggregate) in the context of an adnectin-peptide fusion. For a starting molecule we chose T-2635 109 (30), a sequence that was demonstrated to have stronger helical content, broader spectrum, and a higher barrier to resistance than enfuvirtide. However, T-2635 was designed to have a gp41 110 111 binding site shifted several helical turns to the C-terminus from that of enfuvirtide, including a

significant fraction of the N17 region. Theoretically, this would clash with the binding site of the anti-gp41 adnectin. Therefore, designs with successive turns removed from the N-term of the peptide (which bind the C-term end of the N17 adnectin binding site within gp41) were generated.

116 Fusions of these peptides with a non-optimized member of the anti-gp41 adnectin family 117 and a non-HIV specific adnectin were produced and assayed for potency. It was believed that 118 this approach would best evaluate the potential for antagonism through binding competition and synergy through potency improvements. An initial study was performed and showed that linkage 119 of the fusion inhibitor peptide can act synergistically when linked to an anti-gp41 adnectin. 120 Different length peptides linked identically to either an inert adnectin or the non-optimized anti-121 122 gp41 adnectin 4773_A08 (22) were examined for inhibitory activity (Figure 1). Peptides of 30, 123 32 or 37 amino acids in length were linked to the carboxy terminus of the two adnectins with 124 identical linkers. The potencies of the peptides joined to the non-specific adnectin were inversely correlated to the length, with EC₅₀s of >200 nM, 141 nM and 3.2 nM for the 30, 32 and 37 125 126 amino acid long peptides. Joining the 30 and 32 amino acid peptides to the anti-gp41 adnectin 127 produced synergistic potencies that were much stronger than either of the individual components. 128 Fusions to the longest peptide did not significantly increase the potency, as the EC_{50} for the 129 combination was 1.1 nM, while that of the peptide itself was 3.2 nM. Joining the peptide with the anti-gp41 adnectin has a large synergistic effect on potency when the inhibitors are relatively 130 131 weak, but the effect may be less pronounced when at least one of the inhibitors is optimized for stronger binding. Therefore, additional optimization work was carried out with shorter, weaker 132 peptides so that improvements in potency and synergy could be more readily seen. 133

134 The sequence of the peptide was further optimized by using structural models, which 135 identified nine amino acids that were likely to point into solvent when the peptide is bound. 136 Starting with a protein which consists of an inert adnectin fused to a shortened peptide fusion inhibitor (PRD-1022; Supplemental Table 1), a small library was generated from oligos with 137 degenerate positions, such that in each member of the library, one of the nine positions was 138 139 The peptide with the nine randomized positions randomized. underlined is: 140 SRIEALIRAAQEQQEKNEAALRELDKWAS. One hundred sixty-three separate sequences were expressed and tested for potency. Most of the positions did not show any improvement 141 upon mutation (not shown), but the Asp residue (DKWAS) was profoundly sensitive to changes, 142 143 showing improvements of up to 50-fold when mutated to hydrophobic residues larger than valine (Figure 2) (32, 33). A tyrosine was chosen in the final construct based upon the high potency and 144 the biophysical properties of the adnectin-peptide molecule. Adding the optimal N-terminal 145 146 sequence element into this peptide gave the sequence ultimately used in our clinical candidate, 147 GSK3732394: TIAEYAARIEALIRAAQEQQEKNEAALRELYKWAS.

Antiviral properties of the peptide fusion inhibitor: The 35 amino acid sequence was made 148 149 into a standalone peptide (named 203613-24) in order to measure its potency and binding 150 characteristics. Because a glycine-based linker would ultimately be used to connect this peptide 151 to an anti-gp41 adnectin, the 203613-24 synthetic peptide included an additional glycine residue 152 in the N-terminal position to provide a similar context. The antiviral potency of this isolated 36-153 amino acid peptide was measured in a multiple cycle experiment against a luciferase-expressing NL₄₋₃ virus. 203613-24 exhibited sub-nanomolar inhibition, with an EC₅₀ of 0.40 \pm 0.27 nM 154 155 (Table 1). The molecule also showed no cytotoxicity in cell culture against MT-2 cells, with a CC_{50} of >10,000 nM. In order to assess the binding of the isolated peptide component to gp41, 156

157 we designed a 5-helical bundle protein (PRD-828; Supplemental Information) using the 158 sequences from gp41 that are thought to contact the peptide. The single chain molecule has all 159 three inner helices, and two of the outside helices with connecting linkers, leaving one outer slot open for the peptide to bind. Biotinylated PRD-828 was captured onto a neutravidin-coupled 160 surface of a CM5 Biacore T200 SPR chip, and the 203613-24 peptide was flowed over in 161 162 solution at various concentrations. The peptide exhibited binding to the artificial gp41-like trimer substrate, with a k_a of 2.3 x 10⁶ (1/Ms), a k_d of 2.5 x 10⁻⁴ (1/s) and a K_D of 0.1 nM (Table1). 163 Experiments were conducted under physiological buffer conditions and temperature (37°C). 164

165 Resistance to the isolated peptide inhibitor: In order to select viruses resistant to 203613-24 in 166 cell culture, MT-2 cells were infected with NL_{4-3} virus in the initial presence of a 2X EC₅₀ 167 concentration (~0.8 nM) of the peptide and passaged in increasing concentrations of inhibitor. C. Virus with decreased susceptibility to the peptide was identified at passage 11 (33 days in 168 culture) at a final peptide concentration of 0.51 μ M. The virus population at passage 11 was 169 170 examined and found to have a reduced susceptibility to 203613-24 of ~18-fold. Population 171 sequencing of the virus stocks identified a single amino acid change of V549A (V38A when 172 amino acid numbering is initiated at gp41) compared to the control virus. This amino acid is 173 within the proposed binding site for the peptide, thus confirming the target of the inhibitor. Even though the sequences of 203613-24 and enfuvirtide are different, it has been reported that this 174 175 V549A substitution is selected by enfuvirtide and is a common clinical resistance mutation (34). 176 Given this overlap with a known enfuvirtide resistance mutation, we examined 5 additional 177 known enfuvirtide resistant mutations for their effect on peptide susceptibility. Table 2 shows 178 that the peptide retains good activity against most of these enfuvirtide resistant mutations, 179 exhibiting a reduced susceptibility only to V549A (V38A), and even in this case, enfuvirtide has

an order of magnitude greater fold change in response to the V38A mutation. Thus, although the
peptide exhibits some cross-resistance to enfuvirtide resistance mutations, it tends to exhibit a
more restrictive and potent profile.

183 **Creation of a tri-specific inhibitor.** The length of the G_4S -based linker used to connect the 184 peptide to the carboxy end of the anti-gp41 adnectin was then optimized as described in Table 3. As done previously, a shortened, weaker form of the peptide was used to more readily observe 185 186 changes in synergistic potency. Adnectin-peptide fusion constructs were made with (G₄S)-based linkers. We hypothesized that linker length may affect the synergy between the adnectin and 187 188 peptide, and that the C-terminal residues of the adnectin could also affect the synergy. Therefore, a series of molecules was made with different carboxy termini on the adnectin (4773_A08), and 189 190 with different linker sequences. Table 3 shows the sequences of the adnectin C-terminus, linker, 191 and peptide used. Based upon these data, the C-terminus of the anti-gp41 adnectin in the final 192 molecule altered NYRTP and the linker was to sequence used was 193

194 The potencies of the individual inhibitors, combinations of two inhibitors, and the trispecific inhibitor (all are the made from the final optimized adnectins and peptide) are shown in 195 196 Table 4. A non-HIV specific adnectin was used to substitute for either the anti-CD4 or anti-gp41 197 adnectins in some of the constructs in order to retain the molecular geometry and context, while allowing the dissection of the relative contributions of the individual inhibitors to potency. The 198 199 linker sequences used were also the optimized linkers from the final tri-specific molecule (full 200 sequences of each molecule are shown in Supplemental Table 3). Addition of an inert adnectin in 201 tandem with an optimized, active adnectin (X_41_ and C_X_, where X is the non-specific 202 adnectin, C the anti-CD4 adnectin and 41 the anti-gp41 adnectin) decreased the potency of the

active moiety (~5.6-fold for the anti-CD4 adnectin and ~21.6-fold for the anti-gp41 adnectin), while having the two active moieties (C_41) synergistically increased potency to 0.02 ± 0.01 nM (22). Interestingly, addition of the peptide to the bi-specific adnectin molecule drops the EC₅₀ ~4X to 0.09 ± 0.01 nM. Good activity is also observed when the non-specific adnectin is swapped for the anti-gp41 adnectin in the presence of the two other inhibitors (C_X_P, where P is the peptide 203613-24; EC50 + 0.21 ± 0.03 nM)), but the potency dropped ~10-fold compared to the C_41_P optimized inhibitor.

Addition of a PK-enhancing element to create the final GSK3732394 molecule: Although 210 the tri-specific molecule is highly potent, for it to be useful as a long-acting antiviral agent, it 211 needs to have a long intrinsic half-life in vivo. Probably as a consequence of their small size, 212 213 adnectins by themselves are known to have a short half-life in vivo, likely due to renal clearance 214 (35). Thus, a pharmacokinetic enhancer (PKE) was required to improve the intrinsic in vivo half-215 life of these molecules. After examining the biophysical, antiviral and PK effects of inserting 216 several different PKE elements at different sites in the molecule, a human serum albumin (HSA) 217 molecule was added to the amino terminus of the anti-CD4 adnectin via a 25-amino acid linker. 218 The resulting molecule is GSK3732394 (formerly BMS-986197) (Table 4), whose sequence is 219 shown in Figure 3.

The effect of adding the human serum albumin on antiviral activity was addressed using two different molecular constructs. One molecule (C_41_P) is the exact match to GSK3732394 except that it is missing the HSA molecule and linker sequence connecting it to the anti-CD4 adnectin. It exhibited an EC₅₀ of 0.09 ± 0.01 nM. The final tri-specific molecule, GSK3732394, exhibits an EC₅₀ = 0.27 ± 0.17 nM (Table 4). Thus, the addition of HSA to the amino terminus of a 3-component molecule maintains good potency, but does decrease it by ~3-fold in the context

226 of C_41_P. In addition, the cytotoxicity of the molecule was examined using an XTT method. 227 There was no cytotoxicity observed up to the highest concentration of GSK3732394 tested (>2.9 228 μ M). Given that the assay measures the metabolism of XTT by mitochondrial enzymes, this suggests that at the concentrations tested, GSK3732394 is neither cytotoxic nor cytostatic. 229 230 Finally, serum binding effects on the potency of GSK3732394 were examined with the addition 231 of 40% human serum. The EC_{50} and EC_{90} values in the presence of human serum were within 2-232 fold of their values without human serum (EC₅₀ fold change: 1.14 ± 0.64 ; EC₉₀ fold change: 1.29 + 0.28). Thus, the presence of human serum does not have a significant effect on the potency of 233 GSK3732394. 234

Binding affinities of inhibitors in the context of GSK3732394 compared to isolated 235 236 inhibitors: In order to examine whether the binding of GSK3732394 to its targets differed from 237 its individual components, the affinity of GSK3732394 was measured by SPR against the 3 targets used for analysis against the individual components (22, 28). Thus, binding of 238 GSK3732394 was measured against human CD4 protein, the N17 containing peptide trimer 239 240 IZN24 (22) and the 5-helical bundle reagent containing the target for the fusion peptide inhibitor 241 (PRD-828). All experiments were conducted under physiological buffer conditions and temperature (37°C). The results are shown in Table 5. The K_D of binding to CD4 is 27-fold 242 243 weaker with GSK3732394 than with 6940 B01 (the anti-CD4 adnectin), due primarily to a slower on-rate. This result correlates data showing that addition of HSA appears to reduce 244 245 potency (Table 4). However, CD4 binding could also be affected by the linkage of the anti-246 gp41adnectin and/or the fusion peptide inhibitor.

The K_D for binding of GSK3732394 to IZN24 was 4-fold weaker than the binding of the isolated anti-gp41adnectin (6200_A08) to IZN24. It is possible that steric hindrance resulting

from attaching the HSA and anti-CD4 adnectin to the anti-gp41adnectin may adversely affect interaction with gp41. Similarly, the binding affinity of GSK3732394 for PRD-828 was 3- to -4fold weaker than the affinity of the isolated peptide component for the same target. Thus, linking the components together into a single molecule does result in decreased binding to their specific targets. However, that is compensated for by the synergies associated with the linkages, which results in increased potencies.

255 High potency of the GSK3732394 at low receptor occupancies: From the antiviral potency and the SPR affinity data (Tables 4 and 5), it is clear that fusing the anti-CD4 adnectin 256 257 (6940 B01) to HSA and to the anti-gp41 adnectin (6200 A08) plus the peptide in the context of GSK3732394 has a detrimental impact on the binding of 6940_B01 to CD4, manifested 258 259 primarily as a slower on-rate. To study this effect further, the isolated anti-CD4 adnectin 260 (6940_B01) and GSK3732394 were assessed for their ability to compete with fluorescently 261 labeled 4945_G06 for binding to CD4 on the surface of MT-2 cells. 4945_G06 is a progenitor of 262 6940 B01 that differs slightly from it, but these differences do not affect the potency of the 263 molecule or its ability to compete with 6940 B01 for binding to CD4 (28). MT-2 cells are used 264 for antiviral EC_{50} determinations, so the binding affinity can be directly compared with antiviral 265 potency. A dose response curve for binding to human MT-2 cells was generated with the 266 4945_G06 molecule and compared with the dose response curve for antiviral potency of this molecule (Figure 4). The EC_{50} for binding to MT-2 cells is 7.0 nM while the EC_{50} for antiviral 267 activity in MT-2 cells is similar (4.9 nM). More importantly, the dose response curves for the 268 269 two activities with the isolated anti-CD4 adnectin were similar and almost super-imposable. This 270 indicates that antiviral potency of the individual adnectin is directly related to binding (in a 1:1

271 fashion) and suggests that saturation of binding to CD4 with the anti-CD4 adnectin as an 272 individual inhibitor must be accomplished in order to obtain complete inhibition of infection.

When GSK3732394 was used to generate a dose response curve for binding to MT-2 273 274 cells, the binding was weaker to cells compared to 6940 B01. The binding was 100-fold weaker, 275 with an EC₅₀ of 200 nM. However, the dose response curve of antiviral activity of GSK3732394 in MT-2 cells is $\sim 4 \log_{10}$ stronger compared to CD4 binding and $> 2 \log_{10}$ better than the antiviral 276 277 activity of 4945_G06 in these MT-2 cells. This suggests that the antiviral activity of 278 GSK3732394 is potent at relatively low receptor occupancy (RO). Further experiments at lower 279 concentrations show that at an EC₅₀ (0.27 nM) concentration of GSK3732394 in cell culture, 280 only ~0.2% of CD4 molecules on MT-2 cells are bound to GSK3732394, while at an EC_{90} 281 concentration of 2 nM, ~1.5% of CD4 receptors are bound to GSK3732394 (data not shown). 282 Thus, potent antiviral activity is observed at relatively low receptor occupancy of the inhibitor on 283 CD4 on the surface of cells. Similar values for cell binding were generated for both the individual adnectin and GSK3732394 using human PBMCs (not shown). 284

285 Selection of GSK3732394 resistant virus in cell culture: In order to select viruses resistant to GSK3732394 in cell culture, MT-2 cells were infected with NL₄₋₃ virus in the initial presence of 286 287 a 2X EC₅₀ concentration (~0.5 nM) of GSK3732394. Drug concentration was progressively 288 increased until reaching 300 nM, then was kept constant at that level through multiple passages. NL_{4-3} virus was also passaged concurrently without GSK3732394 selection as a control. Virus 289 290 growth was observed to be slower in the GSK3732394 selection sample, and 37 passages (175 291 days in culture) were required for the virus to grow well enough to warrant harvesting. At that 292 time, the virus population was examined and found to have an 18-fold reduced susceptibility to GSK3732394. Population sequencing of the virus stocks identified 7 amino acid changes in 293

294 gp160 compared to the control virus (Figure 5). Five of these changes were in the gp120 region, 295 with two (T138I and N301K) destroying potential N-linked glycosylation sites (PNGS). The 296 N301K change was also observed during selection with 6940_B01 (28). There is an additional PNGS located between amino acids 396 and 401; the F396S and S401T mutations may have 297 298 affected the glycosylation occupancy of this site as well. Previous resistance selection using 299 6940_B01 showed that resistance mapped to the loss of glycosylation sites in gp120, similar to 300 that observed with ibalizumab (36). In addition to the changes in gp120, a Q577R substitution 301 was observed in the N17 region. This same change was selected by the anti-gp41 adnectin alone 302 and should render the virus resistant to the individual 6200 A08 component (22). Finally, an 303 L544S substitution was observed in the proposed region targeted by the peptide inhibitor. No 304 other changes were observed in gp160. Recombinant virus containing a gp160 gene with all 7 of 305 these substitutions exhibited a 60-fold loss in susceptibility to GSK3732394. The virus was 306 growth impaired, similar to that observed with the earlier Q577R virus alone (22).

307 Virus populations from approximately every third passage from the selection were 308 collected and viral RNA was purified from a portion of the viral supernatants. The genomes were then population sequenced, while the remaining supernatants were examined for susceptibility to 309 310 GSK3732394. As can be seen from Figure 5, the N301K mutation occurred first at ~30% in 311 passage 9, and it was fixed at ~100% by passage 12. At this passage, the Q577R mutation was first observed in a small percentage of genes ($\sim 20\%$) and was fixed at $\sim 100\%$ by passage 24. 312 Also, at passage 24, all of the other gp120 substitutions were fixed, but the fold-change (FC) 313 associated with this virus was still low. The appearance of the L544S substitution (~50%) at 314 315 passage 33, which was fixed by passage 37, corresponded to the first significant FC of ~18. 316 Thus, a larger FC was observed only when resistance to both anti-gp41 inhibitors emerged.

317	GSK3732394 retains activity against virus resistant to components of the GSK3732394
318	molecule: A potential advantage of joining the individual inhibitor components into a single
319	molecule may be an effect on the resistance barrier compared to the individual components. This
320	was examined using recombinant viruses that contain resistance-inducing mutations to one or
321	more of the individual inhibitors. Recombinant envelope proteins resistant to each of the
322	individual adnectins have been described and were selected above (22, 28), and additional
323	recombinant viruses with resistant mutations to two components (either against the anti-CD4
324	adnectin + anti-gp41 adnectin, anti-CD4 adnectin + peptide or anti-gp41 adnectin + peptide)
325	were constructed and tested. The results of these in vitro studies are shown in Table 6. As
326	expected, the individual components exhibited higher fold-changes against the viruses containing
327	their selected substitutions but were fully active against recombinant viruses containing the
328	resistance-inducing substitutions to the other components. Importantly though, the full length
329	GSK3732394 did not exhibit a noteworthy FC against any of the 3 viruses resistant solely to one
330	of the components. The only viruses where a large FC was observed included both anti-gp 41^{R} +
331	peptide ^R substitutions. Interestingly, in separate experiments, the tri-specific molecule (C_41_P;
332	Table 4) that is missing the human serum albumin molecule and linker was examined against
333	additional recombinant viruses (Table 6) that contained resistance mutations to the anti-CD4
334	adnectin and either the anti-gp41 adnectin or the peptide. As with GSK3732394, a high fold
335	change was observed against virus with resistance to the two gp41 targets (FC = 125), but when
336	examined against either the anti- $CD4^{R}$ + peptide ^R or anti- $CD4^{R}$ + anti-gp41 ^R viruses, full
337	susceptibility was observed (0.3- and 0.4-FC, respectively). This suggests that the enhanced
338	potency in the molecule is being driven mainly by the activity of the gp41 inhibitors, presumably
339	as a result of targeting to the cell membrane through CD4 binding. This demonstrates that joining

340 the components in a single molecule could overcome resistance to any one component, as well as 341 to some of the dual resistant combinations, which suggests that another property of joining the inhibitors into one molecule may be to raise the resistance barrier of the GSK3732394 molecule 342 343 compared to those of the individual components.

344 Breadth of antiviral activity: Previously, a cohort of 124 functional envelope gene populations were used to examine the spectrum of activity for the individual adnectin inhibitors in a cell-cell 345 346 fusion assay (22, 28). This same cohort was used to analyze the breadth of activity of the GSK3732394 biologic molecule. This assay usually shows greater run-to-run variability than an 347 infectious virus assay, so the results are normalized against an LAI envelope clone and expressed 348 349 as fold-change.

The 124 envelope gene populations were derived mainly from clinical samples and span 350 11 different HIV-1 subtypes (22). Figure 6 shows the FC of the cohort compared to the LAI 351 352 envelope. GSK3732394 was active against 100% of these envelopes. Of the 124 gp160 populations, only 2 envelope proteins exhibited an FC >10 in this assay. All 64 subtype B 353 354 envelope proteins and 26 subtype C envelope proteins exhibited little to no fold change in the assay. The only two envelope proteins to exhibit a >10 FC were both from subtype D (11.5-FC 355 356 and 17.3-FC), while 2 other subtype D envelope proteins showed no significant FC. When the 357 population of envelope genes from one of these subtype D viruses was cloned into recombinant virus, it exhibited an FC compared to the control virus of 13.3. When the envelope gene from 358 this subtype D virus was sequenced, Q577K and L544V substitutions were observed, which 359 360 could impact the anti-gp41 adnectin and peptide inhibition and account for the FC seen in this 361 virus. Cloning of the other subtype D envelope did not produce an infectious virus, and sequencing of the gp160 gene did not identify mutations that were likely to impact the anti-gp41 362

inhibitors. When envelope gene populations exhibiting the next highest FCs of 6 or 5.8 were
cloned into recombinant viruses and examined against GSK3732394, the FCs were 1.7 and 0.7,
respectively. This suggests that all other envelopes are highly susceptible to GSK3732394. Thus,
this cell-cell fusion data demonstrates that the GSK3732394 molecule is highly active against the
vast majority of virus envelope proteins, including all 90 of the envelope proteins examined from
the major subtypes B and C.

To confirm the breadth of activity of GSK3732394, it was further examined against a series of primary clinical isolates. A panel of 19 HIV-1 clinical isolates from various Group M subtypes (including subtypes A, B, C, D, F, G and CRF01_AE) and 1 virus each from Group N and Group O were evaluated in dose response experiments. GSK3732394 was active against all the clinical isolates, with EC₅₀s ranging from 0.10 nM to 2.1 nM. (Table 7), confirming the wide spectrum of activity of GSK3732394.

375 Activity of GSK3732394 in a humanized mouse model of infection. In order to examine the 376 potential of GSK3732394 to inhibit virus in vivo, a human immune system was reconstituted in 377 NOG mice with hematopoietic stem cells isolated from human cord blood (37). After 14 weeks of engraftment, mice were infected with the YU2 strain (R5 tropic) via IP injection. Table 8 378 379 shows the activity of the various individual components and GSK3732394 against YU2 virus in 380 cell culture. All molecules were active against this virus, although the potency was slightly decreased compared to NL_{4.3} (Table 4). At Day 37 post infection, mice were analyzed for viral 381 load and evenly distributed into 5 groups of 8 mice each. Viral loads of most mice at the time of 382 GSK3732394 administration were in the 10^5 - 10^6 c/mL range. One group was treated 383 384 subcutaneously (SC) with vehicle only, while one group was given a regimen of RAL + TDF +FTC daily incorporated in the food pellet. Based on an average consumption of 4 g of food per 385

386 day, each animal received daily 2.4 mg of TDF, 2.35 mg of FTC and 19.2 mg of RAL. The other 387 3 groups were treated with GSK3732394, injected SC every 3 days at doses of 4, 12.5 or 32 mg/kg. Every 9 days (every third dose) prior to dosing, blood was taken for viral load and other 388 analyses. The study lasted approximately 2 months (63 days), after which treatment was stopped. 389 390 At this point, most animals were exsanguinated, with the exception of three animals each in the 391 392

ARV treated group and the 32 mg/kg GSK3732394 treated group. These animals were left untreated for an additional 21 days (with blood taken 9 days after treatment termination and at end of study) to probe virus rebound. Treatment with GSK3732394 was generally safe and well 393 394 tolerated. Although some mice died during the two-month course of the study, more died in the 395 vehicle and ARV groups (3 and 2 mice, respectively) than in the GSK3732394 treatment groups (1 each of the 4 and 32 mg/kg treatment groups). 396

397 The receptor occupancy of GSK3732394 on CD4 was measured every 9 days (Figure 7a). Variability was observed within each cohort, but a clear dose dependent increase in RO is 398 observed, with the RO among animals in each cohort falling within a ~20% range. The 4 mg/kg 399 400 dose produced the lowest RO, between a few percent and $\sim 25\%$ at each time point, while the 32 401 mg/kg dose exhibited ROs between ~40-60% at the various time points. The 12.5 mg/kg dose 402 was intermediate with respect to RO (~20-40%).

403 As expected, the plasma concentrations of GSK3732394 correlated with the RO values (Figure 7b). A dose dependent increase in plasma concentrations was observed and remained 404 405 consistent throughout the study. There was greater variability in the plasma concentrations at the 406 highest dose compared to the lower doses, especially the 4 mg/kg dose.

407 A summary of the average viral loads for each group at the indicated time points are shown in Figure 8. Interestingly, the vehicle cohort saw approximately a 1 log increase in viral 408

409 titers over the 2 months of the study, while all the inhibitor-treated samples exhibited viral load 410 declines. The data show that at all doses tested, GSK3732394 treatment resulted in significant 411 reductions in viral loads. This even includes the lowest dose cohort (4 mg/kg), which averaged relatively low CD4 receptor occupancy at trough (Figure 7) throughout the study. In the 412 GSK3732394 treated cohorts, a dose dependent decline in viral load was observed, with the 413 414 highest dose seeing almost a 4 \log_{10} drop over the course of the study compared to titers at the 415 start of the experiment. However, all three GSK3732394 treated dose cohorts tended to show an increase in viral load beginning from Days 36 - 45 until the end of the study. Thus, by Day 63, the 416 average viral load decline was over 3 log10 for the 32 mg/kg group and slightly lower and higher than 1 417 log₁₀ for the 4 and 12.5 mg/kg groups, respectively. In addition, there were mice in certain groups 418 whose viral loads were below quantitative levels at certain times. These are indicated by the numbers 419 shown in Figure 8. Thus, 6/8 animals had undetectable viral titers by Day 36 in the 32 mg/kg group, 420

while by Day 63 it was 4/7 animals, while 2/8 animals in the 12.5 mg/kg group possessed viral loads
below detectable levels at Day 63. By that time, all animals in the ART group (6/6) had undetectable
viral loads.

424 At Day 63, the study was terminated for most mice and plasma was collected from all mice but 3 mice each in the ART treated and 32 mg/kg treated cohorts. Plasma samples were taken from all 425 mice in the 4 mg/kg dose cohort and 7 mice in the 12.5 mg/kg dose cohort that exhibited 426 427 measurable viral titers at Day 63, along with 4 mice from the highest 32 mg/kg dose cohort with 428 viral titers. The gp160 genes were amplified from plasma virus by RT-PCR and the gene 429 products were population sequenced. Amplification was successful in most cases, except for one animal in each of the dose groups. In all samples at Day 63 except one, only one amino acid 430 substitution was observed within the gp160 gene. This was a Q577R change within the N17 431

432 region of gp41. The only sample without this change came from the one mouse in the 32 mg/kg cohort 433 whose titer at Day 63 was below the level of quantitation but had an amplifiable gp160. This mouse contained the wild type Q577 and no other changes. The Q577R mutation was previously shown to elicit resistance 434 to the anti-gp41 adnectin that is part of GSK3732394 (22). 435

Thus, in a humanized mouse model of infection, GSK3732394 was able to significantly 436 437 reduce virus titers, even at relatively low CD4 receptor occupancies. Over time, breakthrough of 438 viruses occurred, and the durability of response was dose dependent over the two-month long 439 duration of the experiment. Breakthrough viruses contained a selected mutation that engendered resistance to the anti-gp41 adnectin portion of GSK3732394. 440

441 Three mice without measurable viral titers in the highest dose group of 32 mg/ml and 3 442 mice in the ART treatment group were continued on study without drug for an additional 21 443 days after Day 63, with plasma taken 9 days after treatment termination (Day 72) and at end of study. Viral titers were measured at both time points, although there was only enough plasma available for 444 445 analysis at the Day 72-time point. In the ART treatment group, one sample (either Day 72 or Day 84) of 446 each of the animals showed a measurable viral titer, while all three animals in the 32 mg/kg GSK3732394 treatment group rebounded to titers similar to that observed at start of GSK3732394 treatment. Plasma 447 samples from Day 72 of these 3 mice were amplified and the gp160 gene was population 448 sequenced. In these samples, two mice contained virus with a wild type O577, while one mouse 449 contained virus with a Q577Q/R mixture. 450

451

452 Discussion

Previously, we described a bispecific inhibitor comprised of an anti-CD4 adnectin (28) 453 linked to an anti-gp41 adnectin targeting the N17 region of gp41 (22). The linkage was 454

455 optimized so while each individual inhibitor possessed single-digit nM EC_{50} potency, the 456 connected molecule was >100-fold more potent than the mixture of the two (22). However, studies suggested that the anti-gp41 adnectin suffered from a relatively low resistance barrier. To 457 address that deficiency and potentially make the molecule effective enough that it could become 458 a long acting anti-retroviral agent, an anti-gp41 antiviral peptide was linked downstream of the 459 anti-gp41 adnectin targeting a region in gp41 similar to enfuvirtide. Addition of the peptide did 460 461 decrease the potency of the molecule (from 0.02 to 0.09 nM) but improved the resistance barrier 462 of the combined molecule by making the molecule fully active against viruses resistant to one of 463 the components.

Once a tri-specific inhibitor was constructed, the next stepping stone was to improve the 464 465 half-life of the molecule to enable it to be administered less frequently than once daily. Adnectins by themselves tend to have short half-lives in humans (35, 38), so a pharmacokinetic 466 enhancing (PKE) molecule needed to be included in the final molecule. After analyzing multiple 467 468 formats, a human serum albumin molecule placed at the amino terminus was chosen as the PKE element. The final molecule GSK3732394 exhibited an EC_{50} of 0.27 + 0.17 nM, which is ~3-fold 469 470 weaker than the molecule without the PKE element, perhaps due to weaker affinity for CD4 471 when the HSA molecule is present. GSK3732394 was active against all viruses and viral 472 envelope proteins in the experimental panel. There was one subtype D virus envelope protein that showed a ~17.3-FC in potency in a cell-cell fusion assay compared to the control. Upon 473 sequence analysis, this envelope protein possessed mutations (Q557K and L544V) that could 474 475 result in decreased susceptibility to both anti-gp41 components, which could explain the result. 476 Table 6 shows that viruses with resistance mutations targeted to both gp41 inhibitors do produce 477 an enhanced fold-change. These mutations in envelope are relatively rare within the LANL

database, with the Q577R mutation found in 1.9% of 5454 sequences (2017 release), while
Q577K was found in only 8 isolates (0.15%). The L544V mutation was found in 2.8% of the
isolates in the LANL.

481 The effect of connecting the 3 independent entry inhibitors together has several 482 advantages compared to a mixture of individual inhibitors. An obvious advantage is the need to progress only one clinical candidate through the development pipeline rather than multiple 483 484 separate molecules, although the added complexity of the macromolecule may make development more problematic. In addition, as observed when the two adnectins are joined or 485 when the two anti-gp41 inhibitors are joined with the correct linkage, improved potency is 486 achieved through multiple synergies. The improvement in potencies is the probable result of an 487 488 avidity effect of placing the inhibitors near their site of action, driven by the binding of the anti-489 CD4 adnectin to its target. The peak synergy probably results from the greatly increased 490 concentration of the two gp41 inhibitor components at the cell surface compared to the concentration if the gp41 inhibitors were floating in plasma. The higher local concentration of 491 492 inhibitors should greatly increase their binding on-rate to gp41, and hence their potency, which is 493 what was seen experimentally even when only the anti-gp41 adnectin was linked to an anti-CD4 494 adnectin (Table 4) (22). Studies on linker length connecting the two adnectins suggest that an 495 optimal distance between the two inhibitors is needed, and if that distance is increased, the potency begins to decrease (22). Thus, GSK3732394 contains linker lengths and compositions 496 that are optimal for the gp41 inhibitors to engage the 3-helix trimer and block it from converting 497 to the 6-helix state. This is similar to the potency increase observed when certain bnAbs are 498 linked in a heterologous mAb to ibalizumab (19). 499

500 Another advantage to linking the three inhibitors can be observed when the molecule is 501 tested against viruses containing mutations known to induce resistance to the various 502 components. Virus containing resistance mutations to one, two or all three inhibitor components were recombinantly generated and examined against the individual inhibitors or GSK3732394 503 (Table 6). Against the individual inhibitors, significant fold changes compared to wild type virus 504 505 were observed as expected against the homologous virus/inhibitor pair. However, viruses 506 containing resistance mutations to only one of the inhibitors did not exhibit a significant fold 507 change (1.1-2.1 FC) against GSK3732394. This compares to >660-FC against the anti-gp41 508 adnectin or 7.0-FC against the peptide inhibitor. A significant fold change against a recombinant 509 virus is observed only if it contains resistance mutations to all 3 component inhibitors (98-FC) or to the two anti-gp41inhibitors (89-FC) in the protein. This suggests that linking the inhibitors 510 lournal of Virology into a single molecule should improve the resistance barrier compared to the individual 511 512 components, since a virus would need resistance to multiple inhibitors to see a phenotypic 513 change. A lack of a significant fold change is also observed in recombinant viruses with 514

resistance to the anti-CD4 adnectin and either of the two anti-gp41 inhibitors (Table 6). Resistance to the anti-CD4 adnectin maps to loss of potential N-linked glycosylation sites in 515 gp120 and does not affect the binding of the adnectin to CD4 (28). Thus, even in these latter two 516 517 doubly resistant viruses, GSK3732394 is bound to CD4, although not producing an optimal 518 antiviral effect. Therefore, this strongly suggests that the high potency observed with GSK3732394 is driven by the anti-gp41 inhibitors, while the synergy is driven by binding of the 519 520 molecule to CD4 through the action of the anti-CD4 adnectin.

521 This enhanced resistance barrier is further exemplified by the length of time it took to 522 select for a fully resistant virus in cell culture (Figure 5). It took approximately 6 months and 33 523 cell culture passages for virus with a significant fold change to be selected against GSK3732394. 524 Interestingly, initial changes were observed as early as passages 9-12, where one PNGS site was lost and the key resistance mutation against the anti-gp41 adnectin (Q577R) appeared, although 525 526 the fold change was still low. Loss of PNGSs is the mechanism of resistance development to the anti-CD4 adnectin, but it took the loss of multiple sites to induce resistance to the individual 527 528 adnectin (28). By passage 24, the Q577R mutation was fixed as well as additional mutations at 529 396/401, these mutations potentially affecting the occupancy of another PNGS between those amino acids. An additional mutation of T138I was fixed at this time point and a mutation at T63I 530 531 was observed at ~30% frequency. The T63I change does not affect a PNGS, but the T138I 532 mutation does delete another PNGS in the envelope (perhaps reducing PGNSs by 3-4), which could affect the susceptibility to the anti-CD4 adnectin. Interestingly, this virus still retained a 533 relatively low fold change. This is not surprising, as even if it has reduced susceptibility to both 534 535 adnectins, data from Table 6 shows that it should still be susceptible to GSK3732394. Peptide 536 resistance due to the L544S change is borne out in the next two sets of sequenced passages (33 537 and 37), where the increase in L544S to 50% and then 100% results in a large jump to 18.7- and 19.7-fold changes. At this point, the virus has selected mutations that reduce susceptibility to all 538 three inhibitors, and thus induce a significant, but not overly high fold change. This could 539 540 suggest that the synergistic potential of the combined molecule allows it to retain a fair amount 541 of activity even when resistance is developed against all individual components.

Perhaps the most advantageous property associated with GSK3732394 is its ability to produce high potency at low levels of CD4 receptor occupancy (Figure 4). At the EC_{50} of GSK3732394, only ~0.2% of CD4 on the cell surface is bound, while at the EC_{90} concentration, only ~1.5% of CD4 is bound by inhibitor. How then is inhibitor bound to such a small

percentage of CD4 protein able to inhibit virus at an EC90 level? The increased local 546 547 concentration of the anti-gp41 inhibitors clearly helps, but the very high percentage (>>95%) of free CD4 molecules on the cell still provides unencumbered target for virus to bind to, while any 548 virus bound to a CD4 protein also bound by GSK3732394 will be inhibited by the anti-CD4 549 adnectin. The most logical explanation is that GSK3732394 can inhibit in trans by having the 550 551 anti-gp41 inhibitors reach out and inhibit fusion of virus bound to a different CD4 molecule on 552 the cell. Based upon the antiviral and biophysical data obtained with GSK3732394, the individual components and the partial progenitor constructs, a structural model to explain the 553 554 high degree of synergy can be proposed. The model takes into account what is known about the 555 stoichiometry of gp160 and the fusion process. For instance, electron microscopy studies show that each HIV-1 virion contains between 7-14 trimer spikes (39, 40). In addition, multiple trimer 556 spikes need to undergo a series of conformational changes to form the fusion pore, which 557 558 initiates virus-cell fusion. (40, 41). In the model, GSK3732394, when attached to CD4 via the 559 anti-CD4 adnectin domain, becomes anchored on the surface of the CD4+ T-cell at an optimal 560 distance from the cell surface to interact with the long lived 3-helix gp41 trimer spike bound to a separate CD4 molecule (Figure 9). 561

The overall effect of the binding of GSK3732394 has a number of aspects. First, it reduces the number of CD4 molecules on a T-cell available for functional attachment of the virus and formation of the fusion pore. For instance, if one has ~50% receptor occupancy at trough, this suggests that for most of the dosing period, more than half of the molecules on the cell are engaged with GSK3732394, which may make it difficult to form a functional fusion pore with multiple proteins if the anti-gp41 components work *in trans*. Second, the higher local concentration of inhibitors should also greatly increase their effective binding on-rate to gp41,

569 and hence their potency. Studies on linker length connecting the two adnectins suggest that an 570 optimal distance between the two inhibitors is needed, and if that distance is increased, the potency begins to decrease (22) Thus, GSK3732394 contains a linker length that is optimal for 571 the gp41 inhibitors to engage the 3-helix trimer and block it from converting to the 6-helix state, 572 and since the gp41 inhibitors probably work in trans, the mobility of the drug-bound CD4 573 574 molecules, and their ability to deliver the gp41 inhibitors to the sites of the fusion intermediates 575 during the brief window in which they are accessible, is likely a key to the mechanism of action. The overall result is that inhibition by the complete GSK3732394 is much more potent than the 576 577 sum of its parts.

In order to probe its ability to inhibit virus infection in vivo as a long acting agent, 578 579 GSK3732394 was examined in a humanized mouse model of infection. Humanized mice were 580 infected with virus for 37 days and then treated every three days subcutaneously with either 4, 581 12.5 or 32 mg/kg of GSK3732394 for 63 days. The animals showed a dose dependent increase in 582 CD4 receptor occupancy and a dose dependent decrease in viral load, with 4/7 animals at the 32 mg/kg dose exhibiting viral titers below the level of detection by Day 63 of dosing. 583 GSK3732394 was effective at all 3 doses in a dose dependent fashion, with $\geq 1 \log_{10}$ decrease in 584 585 viral titers after 9 days in the 12.5 and 32 mg/kg dose groups, with the 4 mg/kg dose group 586 decreasing viral titers 1 \log_{10} by Day 27. Thus, GSK3732394 is effective as an antiviral agent in vivo. The 32 mg/kg dose produced viral load decreases of $>3 \log 10$ by Day 27 and the profile 587 was similar to that seen when mice were treated with a daily regimen of RAL, 3TC and TDF. In 588 the 4 and 12.5 mg/kg dose groups, viral titers began to rebound between Days 36-45. Receptor 589 590 occupancies in the highest dose group were between 40-60% at trough, with lower ROs at the 591 lower doses. At Day 63, plasma from all but one mouse contained the single Q577R mutation

592

593 Thus, Q577R was probably selected over the dosing term by GSK3732394. Although in vitro a 594 virus with a Q577R substitution should retain susceptibility to GSK3732394 (Table 6), the potentially suboptimal concentrations of GSK3732394, illustrated by the receptor occupancies in 595 596 Figure 7, probably allows for this selection and virus breakthrough. One can envision a scenario 597 whereby at the lower ROs, occasionally there will be a situation where a GSK3732394-bound 598 CD4 is not close enough to a gp160 bound CD4 to allow for inhibition by the anti-gp41 components in trans, so the virus can infect the cell. Once infected, GSK3732394, as an entry 599 600 inhibitor, has no effect on the infected cell, which can produce new virions. From these and 601 resistance selection studies, it appears that the anti-gp41 adnectin has the lowest resistance 602 barrier of the 3 inhibitors, as it is the first mutation selected in vivo. Even, at the highest dose of 603 32 mg/kg, the RO of 40-60% may be enough to suppress some, but not all mice from selecting 604 Q577R. In this animal model, higher RO may be needed for GSK3732394 dosed as 605 monotherapy to completely suppress virus and avoid the selection of Q577R during longer term 606 treatment. All in all, these data describe a novel tri-specific inhibitor of HIV-1 virus-cell fusion 607 that has the potential to be a long acting inhibitor of virus infection. Although GSK3732394 608 could be used as a part of a long acting HAART regimen, achievement of high receptor 609 occupancy levels may allow it to be used as a standalone therapy under certain conditions. As 610 with all biologic proteins, a current unknown is the potential immunogenicity of the molecule and the effect this might have on its potency and pharmacokinetic properties. Subcutaneously 611 612 dosed GSK3732394 has begun Phase 1 studies in order to answer these questions and to study its 613 potential as a long acting antiretroviral agent.

(the only change seen in any sample) reflective of resistance selection to the anti-gp41 adnectin.

614

615

616 Materials and Methods

Expression and purification of adnectin-peptide molecules. Adnectins with different linkers and/or peptides at the carboxy end of the anti-gp41adnectin were expressed with His tags at the amino terminus of the adnectin and purified via cobalt affinity chromatography as described (28).

621 Expression and purification of GSK3732394. GSK3732394 was expressed via transient 622 transfection of HEK293-6E cells. Briefly, HEK 293-6E cells were seeded into a 1-L shake flask containing 350 mL of F17 medium (Invitrogen) supplemented with Glutamax (0.3 mM; 623 Invitrogen) and Pluronic F68 (0.1%; Invitrogen) at a density of 7×10^5 cells/mL. Cells were 624 grown overnight at 37°C, 5% CO₂, 80% humidity with shaking at 110 RPM. The following day, 625 cells were transfected with expression plasmid DNA using the Polyplus Transfection Reagent 626 627 PEIpro (VWR) according to the manufacturer's recommendations. The day after transfection, 628 cells were fed with 18 mL/flask of 20% Tryptone N1 (Fisher Scientific). Cells were cultured for an additional 5 days. Harvest of conditioned medium was accomplished by centrifugation to 629 630 pellet cells.

GSK3732394 was purified using three chromatography steps followed by a final
ultrafiltration/diafiltration (UFDF) step for concentration and formulation. Initially, hydrophobic
interaction chromatography (HIC) purification was accomplished with a Toyopearl butyl 650M
column (Tosoh). The eluate was then subjected to additional chromatography using 40 μM type
I ceramic hydroxyapatite resin (BioRad). Anion-exchange chromatography using a Poros HQ50
column was employed as a final polishing step. The final eluate was concentrated to 10 mg/ml

637 using a Millipore Pellicon 2 50 Kd 0.1M² membrane and then buffer exchanged with 6 volumes
638 of 25 mM phosphate, 150 mM trehalose, pH 6.8. Post concentration, the product was spiked to
639 0.1% pluronic F68 and sterile filtered.

Kinetics of binding to defined targets. Determination of the binding kinetics of the two 640 641 individual adnectins has been described (22, 28). Binding activity of the peptide component was determined using His-tagged PRD-828 (Supplemental Table 2). This peptide contains three 642 identical sequence segments from the HR1, and two segments from the HR2 regions of gp41, 643 and spontaneously forms a five-helix bundle, displaying a single open peptide binding site, 644 analogous to that described (42). By design, PRD-828 contains only the stretch of gp41 involved 645 in peptide binding, and does not include the N17 region. Neutravidin (Pierce) was diluted to 10 646 647 µg/mL in 10 mM acetate, pH 4.5, and immobilized on a T-series CM5 Biacore chip (GE Healthcare) via a standard amine coupling kit (GE Healthcare) to a level of 6200 RU. The 648 neutravidin surface was conditioned with three injections of 1 M NaCl, 40 mM NaOH. 649 650 Biotinylated 5-helix bundle peptide PRD-828 was diluted in running buffer (HBS-P+; GE 651 Healthcare) to 10 nM and flowed over the neutravidin surface until 122 RU had accumulated. 652 GSK3732394 diluted in running buffer was flowed over the captured PRD-828 surface at 37°C at various concentrations at a flow rate of 50 µL/min with a contact time of 3 min. Dissociation 653 was measured for 2 min or 10 min. A surface consisting of non-binding peptide biotin-IZIZ 654 655 (Supplemental Table 2) captured onto neutravidin was used for reference subtraction, and buffer-656 only samples were included for background subtraction. The PRD-828 surface was regenerated between cycles with two injections of 0.1% SDS. A 1:1 Langmuir binding model was fit to the 657 double-referenced sensorgrams to determine kinetic parameters using Biacore T100 Evaluation 658 Software, version 2.0.1 (GE Healthcare). 659

660 Cells, viruses and antiviral assays. MT-2, HEK 293T, CEM-NKR-CCR5-Luc cells, the 661 proviral DNA clone of NL₄₋₃, and primary clinical isolates were obtained from the NIH AIDS 662 Research and Reference Reagent Program. B6 cells were also used and contain an integrated copy of a luciferase marker gene driven by the HIV-LTR (43). The replication competent $NL_{4,3}$ 663 variant RepRlucNL virus expresses Renilla luciferase and was used for most antiviral assays as 664 665 described (44). Populations of envelope clones were obtained and used as described (28). 666 Cytotoxicity was determined in MT-2 cells after 4 days incubation using XTT (2,3-bis-(2methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) to measure cell viability using 667 668 an established protocol (45).

669 Primary clinical isolates were examined for susceptibility to GSK3732394 using the CEM-NKR-CCR5-Luc cells as a reporter line. The human T-cell line, CEM-NKR-CCR5-Luc 670 expresses CD4, CXCR4 and CCR5 receptors on its cell surface and carries the luciferase reporter 671 672 gene under transcriptional control of the HIV-2 LTR. (46) For susceptibility analyses, the virus 673 was used to infect CEM-NKR-CCR5-Luc cells in the presence or absence of serial dilutions of compound. On the assay set up day, 5×10^6 cells were prepared per 96 well plate and were 674 concentrated via low speed centrifugation at 1000 rpm and resuspended in 0.5 ml. HIV-1 viruses 675 were incubated with the cells at $37^{\circ}C/5\%$ CO₂ for 1 hour within the range of MOI of 0.005 to 676 677 0.01. Serial four- or five-fold dilutions of GSK3732394 or other inhibitors were diluted in a 10 678 µl volume on a 96 well black/clear bottom plate. The cell-virus mix was diluted to the proper 679 volume using assay media (RPMI 1640 supplemented with 10% heat inactivated fetal bovine 680 serum (FBS), 100 units/ml penicillin /100 µg/ml streptomycin, 10 µg/ml polybrene) and 190 µl was added to each well culture plate. The cultures were incubated at 37°C/5%CO₂ for 5-8 days 681 682 and the assay was processed and quantitated for virus growth by the amount of expressed

683 luciferase using the Bright-glo Luciferase kit (Promega). Susceptibility of viruses to inhibitors 684 were determined by XL-Fit analysis of luciferase signals. The results from 2 experiments were averaged to establish the EC_{50} values. 685

Resistance selection. Two million MT-2 cells were infected with NL4-3 virus in the presence of a 686 2X EC_{50} inhibitor concentration at an MOI of 0.005 to 0.05. Syncytium formation as a marker 687 for viral infection was monitored. When syncytium formation reached ~>10%, 1/1000 to 1/100 688 volume of the infectious supernatant was then transferred to fresh MT-2 cells in the presence of 689 the inhibitor at an increased concentration of 2X stepwise. When consistent virus breakthrough 690 691 was observed, the viral supernatant was evaluated against the inhibitor in the B6 antiviral assay. a potency shift of more than 10-fold usually indicates the appearance of resistant virus. The 692 693 infected cells or the viral supernatants were used to obtain the viral genomes by PCR or RT-694 PCR, followed by sequencing to identify the amino acid changes. Amino acid changes were then introduced to viral genome using site-directed mutagenesis and cloning. The recombinant viruses 695 696 were evaluated in a replicating virus assay for potency shift vs. wild type virus.

697 Mouse model and efficacy studies. GSK3732394 was examined for efficacy in a humanized 698 mouse model of HIV infection established and running at TransCure bioServices SAS (Archamps, France). NOD/Shi-scid/IL-2Rynon-specific immunodeficient mouse strain (NOG) 699 700 was humanized with hematopoietic stem cells isolated from cord blood. After reconstitution of 701 the human immune system and confirmation of the presence of CD4+ cells (about 14 weeks 702 post-transplant), the hu-mice were infected with HIV-1 YU2 strain. A total of 40 mice with 703 >25% of circulating human CD45+ were used in the study. Selected hu-mice were inoculated 704 with the HIV YU2 strain by intra-peritoneal injection. Infection proceeded for 31 days after 705 which plasma was obtained to assess viral loads by qRT-PCR and the level of human CD4+ cells

706

707 CD4 cells across the different groups. There were 3 groups treated with GSK37323794; 4, 12.5 708 and 32 mg/kg, along with a vehicle treatment group and a control HAART treated group given 709 raltegravir, lamivudine and tenofovir disproxil fumarate in their food. The GSK3732394 and 710 vehicle treatment groups were dosed SC starting on Day 37 post infection every 3 days, while 711 the HAART treatment group was dosed daily in food. Dosing continued for an additional 60 712 days (20 doses). At every third dose (9 days) during the dosing schedule, plasma was obtained prior to the SC injection for analysis of viral loads and receptor occupancy. At Day 63 post-713 dosing (Day 100 post virus infection), most mice were sacrificed, except for 3 mice in the 714 715 HAART treated group and 3 mice in the 32 mg/kg dosed group. Those mice were kept for an additional 21 days without drug treatment to look at virus rebound. Plasma was obtained from 716 these animals after 9 days and at the end of the experiment. 717

by flow cytometry. Mice were placed into 5 groups, normalizing HIV viral loads and human

718 Viral loads were determined using 20µl of extracted plasma. HIV loads were determined 719 using the "Generic HIV Charge Virale" quantitation kit (Biocentric, France). HIV loads were 720 considered not detectable when Ct values were lower than 37. Limit of sensitivity was estimated 721 to be 500 copies/ml. Receptor occupancy of GSK3732394 was determined via flow cytometry on an Attune NxT Flow Cytometer (Life Technologies). Human immune hematopoietic sub-722 723 populations were monitored using FITC anti-human CD3 (Miltenyi Biotec), anti-CD4 mAb OKT4 (BioLegend), Brilliant Violet 510 anti-human CD8 (BD Biosciences) and an AlexaFluor 724 725 647 labeled anti-CD4 adnectin, 4945_G06-107 (28).

726 Receptor occupancy of GSK3732394 was determined via flow cytometry on an Attune 727 NxT Flow Cytometer (Life Technologies). OKT4 does not compete with GSK3732394 for binding to CD4, and therefore can be used as a marker for CD4+ cells regardless of the presence 728

of GSK3732394. The AF647-4945_G06 adnectin does compete with GSK3732394 for binding
to CD4, and is used as a probe for occupancy. For each timepoint, the AF647 median
fluorescence intensity (MFI) of the CD4+/CD8-/CD3+ cell population from vehicle control
animals was indicative of 0% occupancy, and the AF647 MFI of the CD4-/CD8+/CD3+
population from GSK3732394-dosed animals was used as a surrogate for 100% occupancy. The
% RO for a given sample was then calculated using this equation:

$$\% RO = 100 * (1 - \frac{Sample AF647 MFI_{CD4+CD8-CD3+} - Sample AF647 MFI_{CD4-CD8+CD3+}}{Vehicle AF647 MFI_{CD4+CD8-CD3+}})$$

Plasma levels of GSK3732394 were quantitated via an ELISA assay. Streptavidin-coated 735 black 96-well plates were coated with biotinylated PRD-828 at 1 ug/ml in PBST (Invitrogen) for 736 737 1 hour at room temperature. The coated plates were washed 3 times with PBST and then incubated with SuperBlocker T20 (Thermo Scientific) blocking buffer for 1 hour. The plates were 738 washed 3 times with PBST and mouse plasma samples were serially diluted 5-fold and added to 739 the assay ready plate. The plates were incubated at room temperature with shaking for 1 hour and 740 washed 3 times with PBST before 1:20000 diluted Goat pAb anti HSA-HRP antibody (AbCam) 741 was applied for 30 minutes. Plates were washed 3 times with PBST and developed with 742 743 Supersignal ELISA pico substrate (Thermo Scientific). Signals were read on an EnVision plate 744 reader. Concentrations were determined through comparison with a standard curve, which was 745 created through 3-fold dilutions of GSK3732394 in PBST with added normal mouse plasma 746 (VWR).

For PCR amplification of gp160 genes in mouse plasma, HIV-1 viral RNA was
extracted from 200 µl of mice plasma samples using a QIAamp MinElutevirus kit and eluted
in 40 µl of RNase-free water. cDNA was generated from 34 µl viral RNA using SuperScript
III first strand synthesis kit (Invitrogen) per the manufacturer's protocol. Eighty µl of cDNA

<u>Journal</u> of Virology

751 solution was run over the MinElute PCR Purification Kit (Qiagen) and eluted in 10 µl of EB buffer per manufacturer's protocol. Amplification used YU2 specific primers outside of the 752 753 envelope gene using the Platinum Taq polymerase High Fidelity kit (Invitrogen) The first-754 round PCR product was purified using a MinElutePCR Purification Kit, eluted in 10 µl of EB 755 buffer and used as template for the second round of PCR. Amplified envelope PCR products 756 were subjected to population-based sequencing using a library of envelope-specific primers. 757 The HIV-1 env sequences from the mice were aligned to the YU2 sequence obtained from TransCure using AlignX software in the Vector NTI package (Invitrogen). 758

759

760 Acknowledgments

The authors would like to acknowledge Mei Sun, Yulia Benitez, Dieter Drexler and many other present and former employees of Bristol-Myers Squibb for their support of this program. ViiV Healthcare has assumed responsibility for clinical development of GSK3732394.

Most authors were employees of Bristol-Myers Squibb at the time of this work andmany of those are currently employed by ViiV Healthcare.

767

 \leq

References

- Corado KC, Caplan MR, Daar ES. 2018. Two-drug regimens for treatment of naive HIV-1 infection and as maintenance therapy. Drug Des Devel Ther 12:3731-3740.
 Kelly SG, Nyaku AN, Taiwo BO. 2016. Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere? Drugs 76:523-31.
 Margolia DA, Congular Corgin L Stallbrink HL Eron H. Vagdappaneh Y. Padapmarar
- Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y, Podzamczer
 D, Lutz T, Angel JB, Richmond GJ, Clotet B, Gutierrez F, Sloan L, Clair MS, Murray M,
 Ford SL, Mrus J, Patel P, Crauwels H, Griffith SK, Sutton KC, Dorey D, Smith KY,
 Williams PE, Spreen WR. 2017. Long-acting intramuscular cabotegravir and rilpivirine
 in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label,
 phase 2b, non-inferiority trial. Lancet 390:1499-1510.
- Spreen W, Williams P, Margolis D, Ford SL, Crauwels H, Lou Y, Gould E, Stevens M, Piscitelli S. 2014. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J Acquir Immune Defic Syndr 67:487-92.
- 5. Kerrigan D, Mantsios A, Gorgolas M, Montes ML, Pulido F, Brinson C, deVente J, Richmond GJ, Beckham SW, Hammond P, Margolis D, Murray M. 2018. Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain. PLoS One 13:e0190487.
- Beccari MV, Mogle BT, Sidman EF, Mastro KA, Asiago-Reddy E, Kufel WD. 2019.
 Ibalizumab: A novel monoclonal antibody for the management of multidrug resistant HIV-1 infection. Antimicrob Agents Chemother doi:10.1128/AAC.00110-19.
- 792 7. Dhody K, Pourhassan N, Kazempour K, Green D, Badri S, Mekonnen H, Burger D,
 793 Maddon PJ. 2018. PRO 140, a monoclonal antibody targeting CCR5, as a long-acting,
 794 single-agent maintenance therapy for HIV-1 infection. HIV Clin Trials 19:85-93.
- 8. Sok D, Burton DR. 2019. Publisher Correction: Recent progress in broadly neutralizing antibodies to HIV. Nat Immunol 20:374.
- 9. Sok D, Burton DR. 2018. Recent progress in broadly neutralizing antibodies to HIV. Nat Immunol 19:1179-1188.
- Wagh K, Seaman MS, Zingg M, Fitzsimons T, Barouch DH, Burton DR, Connors M, Ho
 DD, Mascola JR, Nussenzweig MC, Ravetch J, Gautam R, Martin MA, Montefiori DC,
 Korber B. 2018. Potential of conventional & bispecific broadly neutralizing antibodies
 for prevention of HIV-1 subtype A, C & D infections. PLoS Pathog 14:e1006860.
- Bar-On Y, Gruell H, Schoofs T, Pai JA, Nogueira L, Butler AL, Millard K, Lehmann C,
 Suarez I, Oliveira TY, Karagounis T, Cohen YZ, Wyen C, Scholten S, Handl L, Belblidia
 S, Dizon JP, Vehreschild JJ, Witmer-Pack M, Shimeliovich I, Jain K, Fiddike K, Seaton
 KE, Yates NL, Horowitz J, Gulick RM, Pfeifer N, Tomaras GD, Seaman MS,
 Fatkenheuer G, Caskey M, Klein F, Nussenzweig MC. 2018. Safety and antiviral activity
 of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat Med
 24:1701-1707.
- Caskey M, Klein F, Nussenzweig MC. 2019. Broadly neutralizing anti-HIV-1
 monoclonal antibodies in the clinic. Nat Med doi:10.1038/s41591-019-0412-8.

Downloaded from http://jvi.asm.org/ on August 13, 2019 at ETH Bibliothek Zuerich

13.

812 813

Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral 814 activity. Nat Commun 9:877. 815 14. Khan SN, Sok D, Tran K, Movsesyan A, Dubrovskaya V, Burton DR, Wyatt RT. 2018. 816 Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for 817 Single-Component Broad Inhibition of Entry. J Virol 92. 818 Padte NN, Yu J, Huang Y, Ho DD. 2018. Engineering multi-specific antibodies against 819 15. 820 HIV-1. Retrovirology 15:60. 821 16. Augusto MT, Hollmann A, Castanho MA, Porotto M, Pessi A, Santos NC. 2014. Improvement of HIV fusion inhibitor C34 efficacy by membrane anchoring and 822 823 enhanced exposure. J Antimicrob Chemother 69:1286-97. 824 17. Ingallinella P, Bianchi E, Ladwa NA, Wang YJ, Hrin R, Veneziano M, Bonelli F, Ketas 825 TJ, Moore JP, Miller MD, Pessi A. 2009. Addition of a cholesterol group to an HIV-1 826 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci U 827 S A 106:5801-6. 828 18. Song R, Pace C, Seaman MS, Fang Q, Sun M, Andrews CD, Wu A, Padte NN, Ho DD. 829 2016. Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies. J Acquir Immune Defic Syndr 73:365-373. 830 Pace CS, Song R, Ochsenbauer C, Andrews CD, Franco D, Yu J, Oren DA, Seaman MS, 831 19. Ho DD. 2013. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit 832 exceptional breadth and picomolar potency against HIV-1. Proc Natl Acad Sci U S A 833 110:13540-5. 834 20. 835 Fetzer I, Gardner MR, Davis-Gardner ME, Prasad NR, Alfant B, Weber JA, Farzan M. 836 2018. eCD4-Ig Variants That More Potently Neutralize HIV-1. J Virol 92. 837 21. Fellinger CH, Gardner MR, Weber JA, Alfant B, Zhou AS, Farzan M. 2019, eCD4-Ig 838 limits HIV-1 escape more effectively than CD4-Ig or a broadly neutralizing antibody. J 839 Virol doi:10.1128/JVI.00443-19. 840 22. Wensel D, Sun Y, Davis J, Li Z, Zhang S, McDonagh T, Fabrizio D, Cockett M, Krystal M. 2018. A Novel gp41-Binding Adnectin with Potent Anti-HIV Activity Is Highly 841 842 Synergistic when Linked to a CD4-Binding Adnectin. J Virol 92. Lipovsek D. 2011. Adnectins: engineered target-binding protein therapeutics. Protein Eng 843 23. Des Sel 24:3-9. 844 24. 845 Sachdev E, Gong J, Rimel B, Mita M. 2015. Adnectin-targeted inhibitors: rationale and results. Curr Oncol Rep 17:35. 846 25. Koide A, Bailey CW, Huang X, Koide S. 1998. The fibronectin type III domain as a 847 848 scaffold for novel binding proteins. J Mol Biol 284:1141-51. 849 26. Koide S, Koide A, Lipovsek D. 2012. Target-binding proteins based on the 10th human fibronectin type III domain ((1)(0)Fn3). Methods Enzymol 503:135-56. 850 27. Tolcher AW, Sweeney CJ, Papadopoulos K, Patnaik A, Chiorean EG, Mita AC, Sankhala 851 K, Furfine E, Gokemeijer J, Iacono L, Eaton C, Silver BA, Mita M. 2011. Phase I and 852 853 pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res 17:363-71. 854 Wensel D, Sun Y, Li Z, Zhang S, Picarillo C, McDonagh T, Fabrizio D, Cockett M, 855 28. 856 Krystal M, Davis J. 2017. Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity. Antimicrob Agents Chemother 61. 857

Steinhardt JJ, Guenaga J, Turner HL, McKee K, Louder MK, O'Dell S, Chiang CI, Lei L,

Galkin A, Andrianov AK, N AD-R, Bailer RT, Ward AB, Mascola JR, Li Y. 2018.

- Yi HA, Fochtman BC, Rizzo RC, Jacobs A. 2016. Inhibition of HIV Entry by Targeting
 the Envelope Transmembrane Subunit gp41. Curr HIV Res 14:283-94.
- Bowyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA,
 Matthews TJ, Greenberg ML, Delmedico MK. 2007. Design of helical, oligomeric HIV-1
 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl
 Acad Sci U S A 104:12772-7.
- Huerta-Garcia G, Chavez-Garcia M, Mata-Marin JA, Sandoval-Ramirez J, Dominguez-Hermosillo J, Rincon-Rodriguez AL, Gaytan-Martinez J. 2014. Effectiveness of enfuvirtide in a cohort of highly antiretroviral-experienced HIV-1-infected patients in Mexico. AIDS Res Ther 11:323.
- Seay K, Qi X, Zheng JH, Zhang C, Chen K, Dutta M, Deneroff K, Ochsenbauer C, Kappes JC, Littman DR, Goldstein H. 2013. Mice transgenic for CD4-specific human CD4, CCR5 and cyclin T1 expression: a new model for investigating HIV-1 transmission and treatment efficacy. PLoS One 8:e63537.
- 33. Yu F, Lu L, Du L, Zhu X, Debnath AK, Jiang S. 2013. Approaches for identification of
 HIV-1 entry inhibitors targeting gp41 pocket. Viruses 5:127-49.
- 874 34. Poveda E, Briz V, Soriano V. 2005. Enfuvirtide, the first fusion inhibitor to treat HIV
 875 infection. AIDS Rev 7:139-47.
- 876 35. Kontermann RE. 2009. Strategies to extend plasma half-lives of recombinant antibodies.
 877 BioDrugs 23:93-109.
- Song R, Oren DA, Franco D, Seaman MS, Ho DD. 2013. Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity. Nat Biotechnol 31:1047-52.
- 37. Manfroi B, McKee T, Mayol JF, Tabruyn S, Moret S, Villiers C, Righini C, Dyer M,
 Callanan M, Schneider P, Tzankov A, Matthes T, Sturm N, Huard B. 2017. CXCL-8/IL8
 Produced by Diffuse Large B-cell Lymphomas Recruits Neutrophils Expressing a
 Proliferation-Inducing Ligand APRIL. Cancer Res 77:1097-1107.
- 38. Lin JH. 2009. Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies. Curr Drug Metab 10:661-91.
- Chertova E, Bess JW, Jr., Crise BJ, Sowder IR, Schaden TM, Hilburn JM, Hoxie JA,
 Benveniste RE, Lifson JD, Henderson LE, Arthur LO. 2002. Envelope glycoprotein
 incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary
 determinant of SU content of purified human immunodeficiency virus type 1 and simian
 immunodeficiency virus. J Virol 76:5315-25.
- 40. Zhu P, Chertova E, Bess J, Jr., Lifson JD, Arthur LO, Liu J, Taylor KA, Roux KH. 2003.
 Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci U S A 100:15812-7.
- 895 41. Brandenberg OF, Magnus C, Rusert P, Regoes RR, Trkola A. 2015. Different infectivity
 896 of HIV-1 strains is linked to number of envelope trimers required for entry. PLoS Pathog
 897 11:e1004595.
- 898 42. Root MJ. 2001. Protein Design of an HIV-1 Entry Inhibitor. Science 291:884-888.
- 43. Nowicka-Sans B, Gong YF, McAuliffe B, Dicker I, Ho HT, Zhou N, Eggers B, Lin PF,
 890 Ray N, Wind-Rotolo M, Zhu L, Majumdar A, Stock D, Lataillade M, Hanna GJ,
 901 Matiskella JD, Ueda Y, Wang T, Kadow JF, Meanwell NA, Krystal M. 2012. In vitro
 902 antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active
 903 component of the prodrug BMS-663068. Antimicrob Agents Chemother 56:3498-507.

904 905	44.	Li Z, Terry B, Olds W, Protack T, Deminie C, Minassian B, Nowicka-Sans B, Sun Y, Dicker I, Hwang C, Lataillade M, Hanna GJ, Krystal M. 2013. In vitro cross-resistance
906		profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known
907		NRTI resistance mutations. Antimicrob Agents Chemother 57:5500-8.
908	45.	Weislow OS, Kiser R, Fine DL, Bader J, Shoemaker RH, Boyd MR. 1989. New soluble-
909		formazan assay for HIV-1 cytopathic effects: application to high-flux screening of
910		synthetic and natural products for AIDS-antiviral activity. J Natl Cancer Inst 81:577-86.
911	46.	Spenlehauer C, Gordon CA, Trkola A, Moore JP. 2001. A luciferase-reporter gene-
912		expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either
913		R5 or X4 strains of human immunodeficiency virus type 1. Virology 280:292-300.
914		

915

916

917 FIGURE LEGENDS

918 FIGURE 1 Effect of joining the peptide inhibitor to the carboxy terminus of the anti-gp41 919 adnectin. Potencies of individual fusion peptide inhibitors fused to an inactive adnectin were 920 compared to potencies of the same peptides linked to an anti-gp41 adnectin (4773_A08) (22). 921 The names of each protein are shown above the diagram and the sequences of each of the anti-922 fusion peptides are shown below the figure.

923

FIGURE 2 Potency of peptides with single amino acid substitutions of the Asp. The short
peptide in the PRD-1022 adnectin-peptide fusion was mutated to replace the Asp
(SRIEALIRAAQEQQEKNEAALREL<u>D</u>KWAS) residue with one of 15 other amino acids and
examined for antiviral activity. Absolute EC₅₀s for each adnectin-peptide proteins are shown.

928

FIGURE 3 Amino acid sequence of GSK3732394/BMS-986197. The human serum albumin component is highlighted in red, the anti-CD4 and anti-gp41 adnectins are highlighted in green and blue, respectively, and the peptide is highlighted in purple. The linker sequences are not highlighted. In addition, the human serum albumin component contains a C34A mutation to remove the only free sulfhydryl group in the molecule.

FIGURE 4 Comparison of binding affinity of GSK3732394 to MT-2 cells with antiviral activity observed against RepRLucNL virus. Concentration of GSK3732394 is platted against% maximal activity (binding to CD4 or antiviral activity). The antiviral activity of the anti-CD4 adnectin alone superimposes with its cell binding activity, while the antiviral activity dose response of GSK3732394 is much stronger than that of its cell binding activity.

Journal of Virology

939 FIGURE 5 Selection of GSK3732394-resistant virus. Table at the top lists all the changes 940 observed during selection by passage 37 and the fold change compared to wild type NL_{4-3} virus. 941 Recombinant virus represents a pure RepRlucNL virus containing all the changes shown. For the selection, population sequencing and susceptibility analysis of virus were performed every 3 942 passages (p) and are graphed as fold change (FC) versus wild type virus. GSK3732394 943 944 concentrations are shown on the right. Identified mutations are listed at specific passages in the 945 boxes, with estimated frequencies. If no frequency is listed, mutation was fixed at $\sim 100\%$. 946 FIGURE 6 Observed fold change of cloned envelope populations against GSK3732394 in a 947 **cell-cell fusion assay.** Envelope populations were divided into subtypes as shown above. 948 Subtypes with one or a few envelopes are grouped into Others and the numbers of isolates and 949 color codes are shown to the right. Significant changes in susceptibility were estimated to be 10-950 FC or above, as described in text. 951 FIGURE 7 A) CD4 receptor occupancy with GSK3732394 in the YU2 infected humanized mice 952 and B) GSK3732394 concentrations at trough on the respective days of the study. The doses are indicated by line type and the key is in the figure. Days denote time after first dose (not including 953 954 the 37 days of YU2 infection prior to firt dose). 955 FIGURE 8 Efficacy of GSK3732394 in a mouse model of infection. Lines represent viral titers in 956 dose cohorts, the identities of which are shown on the right. The numbers in fractions indicate the 957 number of samples with undetectable viral load at this time point. Since the lower limit of 958 quantitation of the QPCR assay was 100 copies/ml, for graphing purposed, undetectable

samples were arbitrarily given a viral load of 100 copies/ml.

960 FIGURE 9 Model of inhibition by GSK3732394. The CD4 molecule (A) is bound to the anti-

961 CD4 component of GSK3732394 (B and C). D) A gp41 molecule in the semi-stable 3-helix

962	conformation, as part of a gp160 trimer bound to a different CD4 within the fusion pore. The
963	GSK3732394 - CD4 complex is in the correct orientation and at an optimal distance for the anti-
964	gp41 adnectin and peptide inhibitors to allow them to bind to the gp41 (E), thus disarming 2
965	distinct epitopes on gp41. Color coding for the 3-hHIV-1 gp41: N-terminal fusion peptide
966	domain (teal), helical domain binding to peptide inhibitor (purple), N-terminal "N17" region
967	(green) and C-terminal domain (dark blue).

968

Assessment	Number of replicates		EC ₅₀ (nM)	EC ₉₀ (nM)
Antiviral activity ^a	21		0.40 ± 0.27	5.19 ± 3.53
		$k_{\rm a}$ (1/Ms ⁾	<i>k</i> _d (1/s)	$K_{\rm D}$ (nM)
Target binding activity ^b	3	$4.3 \pm 1.7 \text{ X } 10^6$	$2.4 \pm 0.1 \text{ X } 10^{-4}$	0.06 ± 0.03

Downloaded from http://jvi.asm.org/ on August 13, 2019 at ETH Bibliothek Zuerich

TABLE 1 Antiviral potency and binding affinity of peptide 203613-24

^aTested against RepRlucNL virus

^bKinetic measurements performed using the PRD-828 target

	Potency Fold-Change for Given Variant Relative to LAI Envelope ^a							
Inhibitor	G547D ^b (G36D)	V549A (V38A)	Q551H (Q40H)	N553T (N42T)	N554D (N43D)			
Enfuvirtide	36.4 ± 8.3	167 ± 20	5.7 ± 4.7	9.3 ± 2.7	157 ± 157			
203613-24	1.0 ± 0.6	17.7 ± 7.4	2.4 ± 1.5	2.3 ± 2.3	1.1 ± 0.1			

Downloaded from http://jvi.asm.org/ on August 13, 2019 at ETH Bibliothek Zuerich

TABLE 2 Activity of 203613-24 against envelope proteins in the RepRlucNL with enfuv	irtide
resistance mutations	

^aFold change compared to LAI control envelope in a cell-cell fusion assay ^bMutation numbering based upon HXB2 sequence starting from gp120 or (gp41)

Name	EC ₅₀ (nM)	C-terminal sequence of anti-N17 adnectin	Linker sequence
PRD-2767	4.8	NYRTEIE	GGGGSGGGGGGGGGGGGGGG
PRD-2768	3.0	NYRTEIE	GGGGSGGGGGGGGG
PRD-2769	12.7	NYRTEIE	GGGGSGGGGSG
PRD-2770	10.3	NYRTEIE	GGGGSGGGG
PRD-2771	3.5	NYRTEIE	GGGGSG
PRD-2772	1.0	NYRTEIE	GGGGSGGGGGGGGGGGGGGGGGGGGGG
PRD-2773	3.6	NYRTEIE	GGGGSGGGGGGGGGGGGGGG
PRD-2774	2.1	NYRTEI	GGGGSGGGGGGGGGGGGGGG
PRD-2775	1.2	NYRTE	GGGGSGGGGGGGGGGGGGGG
PRD-2776	1.2	NYRTP	GGGGSGGGGGGGGGGGGGGG

TABLE 3 Or	otimization	of the linke	r between	the anti-gp41	Adnectin and pept	ide ^a

^aAll constructs contained the same peptide fusion inhibitor sequence (SEYEARIEALIRAAQEQQEKNEAALRELDK) C-terminal to the linker except for PRD-2773, which has Ala substituted for the Ser at the amino terminus of the peptide.

 $\overline{\leq}$

Note: This table is also provided as a separate TIF file (graphic file) due to the diagram graphics it contains

Designation	Diagram	$EC_{50}\left(nM\right)^{b}$	Description
С	•	11.4 ± 4.4	anti-CD4 adnectin only
41		6.1 ± 0.1	anti-gp41 adnectin only
Р		0.53 ± 0.16	peptide only
X ^a	0	>1000	inert adnectin only
C_X_	●-◎ -	64.3 ± 18.1	anti-CD4 adnectin_inert adnectin_linker
X_41_	0-	132.1 ± 9.8	inert adnectin_ anti-gp41adnectin_linker
X_41_P	0	61.7 ± 14.8	inert adnectin_anti-gp41 adnectin_peptide
C_41	•-•	0.02 ± 0.01	anti-CD4 adnectin _ anti-gp41 adnectin
C_X_P	●-◎-▶	0.21 ± 0.03	anti-CD4 adnectin_inert adnectin_peptide
C_41_P	●-●-▶	0.09 ± 0.01	anti-CD4 adnectin_ anti-gp41 adnectin_peptide
C+41+P	●+●+▶	0.53 ± 0.02	1:1:1 mixture of the 3 individual inhibitors
GSK3732394	HSA-	0.27 ± 0.17	HSA_anti-CD4 adnectin_ anti-gp41 adnectin_peptide

Downloaded from http://jvi.asm.org/ on August 13, 2019 at ETH Bibliothek Zuerich

TABLE 4 Synergistic and antagonistic properties of joining the anti-HIV-1 adnectins and peptide

 ${}^{a}X =$ non-HIV-1 specific adnectin

^bpotency against RepRlucNL virus; average of 3 independent experiments

inhibitors				
Protein	Target	$k_{\rm a} (1/{ m Ms})$	$k_{\rm d} (1/{\rm s})$	$K_{\rm D}$ (nM)
GSK3732394	Human CD4	$1.3 \pm 0.5 \text{ X } 10^4$	$7.5 \pm 0.7 \text{ X } 10^{-4}$	66 ± 38
6940_B01	Human CD4	$2.0 \pm 0.3 \text{ X} 10^5$	$7.5 \pm 0.5 \text{ X } 10^{-4}$	3.9 ± 0.7
GSK3732394	IZN24 ^a	$9.1 \pm 3.5 \ge 10^5$	$2.2 \pm 1.0 \text{ X } 10^{-3}$	2.4 ± 0.3
6200_A08	IZN24	$4.8 \pm 1.9 \ge 10^6$	$3.5 \pm 0.5 \text{ X } 10^{-3}$	0.8 ± 0.4
GSK3732394	PRD-828	$7.1 \pm 2.2 \text{ X } 10^5$	$2.7 \pm 0.8 \text{ X } 10^{-4}$	0.4 ± 0.2
203613-24	PRD-828	$4.3 \pm 1.7 \text{ X } 10^{6}$	$2.4 \pm 0.1 \text{ X } 10^{-4}$	0.06 ± 0.03

TABLE 5 Binding affinity of GSK3732394 to inhibitor targets and comparison to the individua	1
inhibitors	

^aTarget described in (22)

Inhibitor	Anti- CD4 ^{Ra}	Anti- gp41 ^R Q577R	pep ^R L544S	pep ^R V549A	Anti- gp41 ^R /pep ^R Q577R+ V549A	Anti-CD4 ^R + Anti-gp41 ^R + pep ^{Rb}		Anti- CD4 ^R + gp41 ^R
6940_B01	6.8 ^c	0.1	1.2	nd	0.8	3.2	nd	nd
6200_A08	0.4	>660	1.8	nd	>799.8	>660	nd	nd
203613-24	0.4	1.4	7.0	24.2	83.1	39.9	nd	nd
GSK3732394	1.1	1.9	2.1	6.8	89.1	98.0	nd	nd
$C_41_P^d$	0.5	3.7	1.3	nd	125	nd	0.3	0.4

TABLE 6 Activity of GSK3732394,	individual inhibitors,	and C_41_P against RepRlucNL
viruses with selected mutations that end	code resistance to one of	or multiple components

^aAnti-CD4^R amino acid changes = S143R, N197D, N301K, and S465P ^bVirus contains the anti-CD4^R mutations + Q577R +V549A ^cFold-change in EC₅₀ compared to wild type ReprRlucNL

^dPerformed in independent experiments

nd: Not done

Virus	Subtype	$EC_{50}(nM)$	
92BR018	В	0.71	
92BR028	В	1.95	
10215-6	С	0.11	
97ZA012	С	0.24	
93RW034	А	0.70	
94UG103	А	0.40	
92UG046	D	0.42	
92US660	В	0.26	
92HT599	В	0.10	
JEW	В	0.11	
92UG029	А	0.05	
98TZ017	С	0.06	
94UG114	D	0.20	
92TH001	CRF01_AE	0.19	
RU570	G	1.07	
91US056	В	0.07	
93BR020	F	0.11	
98BR004	С	0.23	
92BR014	В	0.26	
YBF30	Group N	0.85	
BCF03	Group O	2.10	

TABLE 7 Activity of GSK3732394 against clinical isolates					
Virus	Subtype	$EC_{50}(nM)$			
	-				

TAE	BLE 8 Activity	of inhibitors	against YU	J2 virus


Avg $EC_{50}(nM)$
90
238
136
1.2

	Individual Adnectin	Adn + Short Adn + Medium		Adn + Long	
		5598_B01	5626_E10	5586_A01	
		marine Mile	munum	and the second	
EC ₅₀ (nM):	Inactive	>200	141	3.2	
	4773_A08	5626_A01	5626_E09	5626_A10	
		unere the	uneers the	CLANDOUR S	
EC ₅₀ (nM):	48	4.8	0.7	1.1	
	PeptideSequenceShortAEYEARIEALIRAAQEQQEKNEAALRELDK				

Peptide	Sequence
Short	AEYEARIEALIRAAQEQQEKNEAALRELDK
Medium	TIAEYAARIEALIRAAQEQQEKNEAALRELDK
Long	TTWDRAIAEYAARIEALIRAAQEQQEKNEAALRELDK




200-



 \leq


nline
Ō
Posted
script
Manu
Accepted /

	001	DAHKSEVAHR	FKDLGEENFK	ALVLIAFAQY	LQQ <mark>A</mark> PFEDHV	KLVNEVTEFA	KTCVADESAE	060
	061	NCDKSLHTLF	GDKLCTVATL	RETYGEMADC	CAKQEPERNE	CFLQHKDDNP	NLPRLVRPEV	120
	121	DVMCTAFHDN	EETFLKKYLY	EIARRHPYFY	APELLFFAKR	YKAAFTECCQ	AADKAACLLP	180
	181	KLDELRDEGK	ASSAKQRLKC	ASLQKFGERA	FKAWAVARLS	QRFPKAEFAE	VSKLVTDLTK	240
	241	VHTECCHGDL	LECADDRADL	AKYICENQDS	ISSKLKECCE	KPLLEKSHCI	AEVENDEMPA	300
	301	DLPSLAADFV	ESKDVCKNYA	EAKDVFLGMF	LYEYARRHPD	YSVVLLLRLA	KTYETTLEKC	360
of Virology	361	CAAADPHECY	AKVFDEFKPL	VEEPQNLIKQ	NCELFEQLGE	YKFQNALLVR	YTKKVPQVST	420
/iro	421	PTLVEVSRNL	GKVGSKCCKH	PEAKRMPCAE	DYLSVVLNQL	CVLHEKTPVS	DRVTKCCTES	480
	481	LVNRRPCFSA	LEVDETYVPK	EFNAETFTFH	ADICTLSEKE	RQIKKQTALV	ELVKHKPKAT	540
Journal	541	KEQLKAVMDD	FAAFVEKCCK	ADDKETCFAE	EGKKLVAASQ	AALGLGGGGGS	GGGGSGGGGS	600
nof	601	GGGGSGGGGS	GVSDVPRDLE	VVAATPTSLL	ISWDAPAVTV	HSYHIQYWPL	GSYQRYQVFS	660
	661	VPGSKSTATI	SGLKPGVEYQ	IRVYAETGGA	DSDQSFGWIQ	IGYRTPESPE	PETPEDE <mark>GVS</mark>	720
	721	DVPRDLEVVA	ATPTSLLISW	EYKVHPYRYY	RITYGETGGN	SPVQEFTVPS	VLSTAEISGL	780
	781	KPGVDYTITV	YAVTRGVDSA	PISINYRTP G	GGGSGGGGSG	GGGSGGGG <mark>TI</mark>	AEYAARIEAL	840
	841	IRAAQEQQEK	NEAALRELYK	WAS				



Z

Ma								
Accepted								
Acce	-	Virus	Passage Number	Days	Fold Change	T63	T138	N301
	-	NL ₄₋₃ wt	37	175	1	Т	Т	Ν
		Selected virus	37	175	18	I	Ι	K



F394

F

S

S401

S

Т

L544

L

S

Q577

Q

R


Z


30-

15⁻

0


Fold Change








Z



Downloaded from http://jvi.asm.org/ on August 13, 2019 at ETH Bibliothek Zuerich

 \sum



host CD4+ T cell membrane

Ň